All Type of News
Government to increase fines up to 200 million won
Starting next year, companies that were found to violate the regulation will be subject to a fine of up to 200 million from the current 50 million, according to the Korea Food and Drug Administration.
Under the rev...
KFDA chief likely to be replaced in May
Speculation has been growing that President Lee Myung-bak may replace some vice ministers within this month at the latest.
Sources say the Korea Food and Drug Administration Chief Noh Yun-hong is expected to be rep...
KFDA approves Nycomed’s oral COPD therapy
Nycomed Korea has announced that Daxas (roflumilast) was approved by the Korea Food and Drug Administration as an oral treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in pati...
Multinational firms call for innovative drug price reform
Korea is already being recognized for its excellent clinical research and drug development infrastructure, world-class researchers, hospitals and facilities. It is already one of the leading countries in clinical tria...
Kanarb likely to be prescribed in 40 general hospitals in second half
Boryung Pharmaceutical is enjoying brisk sales of its new antihypertensive drug, Kanarb (fimasartan).
Monthly sales of Kanarb is expected to reach 1,000 million won in the first half of this year, as it has succeed...
Wholesalers to face thinner margin
As Japanese drugmakers in Korea are poised to reduce wholesaler margin, hundreds of local wholesalers went up in arms against the new movement, seeing it as a threat to their business.
They established an emergenc...
Baraclude and Viread to drive market growth in Korea
The domestic hepatitis B market is expected to witness significant changes as Yuhan’s Viread (tenofovir) is to be launched in the latter half of this year.
Currently, BMS’s Varaclude (entecavir) has led the domesti...
Hanmi, MSD to cooperate over Amosartan
Hanmi Pharmaceutical and the US based Merck & Co. signed their second contract to sell Hanmi's incrementally modified hypertensive amlodipine product Amosartan in 30 countries, under Merck's brand Cozzar XQ.
The co...
Drug makers’ profitability worsen on aggressive promotion
Domestic pharmaceutical firms, which have increased their revenues during the last few years, are seeing profitability worsen on aggressive promotion.
Yakup com. said most of Korean drug manufacturers are seeing th...
Daewoong’s monthly per capita sales top 42.4 million won per
The per capita sales in Daewoong Pharmaceutical stood at 42.4 million won per month, according to Yakup. com, pharmaceutical information provider.
Yakup. com. said that the average monthly revenue of 49 pharmaceuti...
